Taken together, the data suggest that the targeting of ISCA2 could be a strategy to inhibit HIF-α and induce ferroptosis particularly in pVHL deficient, more aggressive ccRCC cells. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.